X4 PHARMACEUTICALS INC. - COMMON STOCK

X4 Pharmaceuticals Expands Commercial Leadership Expertise with Appointment of Françoise de Craecker to Board of Directors and Karolyn Park as Vice President, U.S. Commercial

19 Oct 2021 08:00:02 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Completes Enrollment in Phase 3 Mavorixafor Trial in Patients with WHIM Syndrome

04 Oct 2021 08:00:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Oct 2021 16:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in Upcoming Investor Conferences

15 Sep 2021 16:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Promotes Mary DiBiase, Ph.D. to Chief Operating Officer

08 Sep 2021 08:00:04 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Sep 2021 16:01:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

01 Sep 2021 08:00:03 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate at Canaccord Genuity’s Virtual 41st Annual Growth Conference

04 Aug 2021 16:01:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Key Enrollment Milestone Achievements in Ongoing Mavorixafor Clinical Trials and Reports Second Quarter Financial Results

03 Aug 2021 08:00:01 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 3, 2021

22 Jul 2021 16:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Jul 2021 16:01:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia at EHA 2021

11 Jun 2021 03:00:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Host Conference Call and Webcast to Present Initial Efficacy and Safety Data from EHA 2021 Poster on Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia

26 May 2021 08:00:01 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in Two May Virtual Investor Conferences

17 May 2021 08:00:02 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Positive Preliminary Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia as Published in EHA Abstract

12 May 2021 10:00:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update

06 May 2021 08:00:02 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 May 2021 16:01:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 6, 2021

22 Apr 2021 08:00:01 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference

07 Apr 2021 08:00:01 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Apr 2021 16:05:00 By Nasdaq GlobeNewswire